View in EDS HTML Full Text PDF Full Text

Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.

Saved in:
Bibliographic Details
Title: Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
Authors: Martinon-Torres F; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain., Lamberth E; Pfizer Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA., Natalini Martinez S; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., Salamanca de la Cueva I; Unidad de Investigación, Grupo IHP (Instituto Hispalense de Pediatría), Sevilla, Spain., Zolotas L; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK., Oladipupo I; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Maguire JD; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., Trammel J; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain., O'Neill R; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Liberator PA; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Peyrani P; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA., Jodar L; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA., Gruber WC; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Anderson AS; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA., Beeslaar J; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK.
Source: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2463194. Date of Electronic Publication: 2025 Feb 24.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Taylor & Francis Country of Publication: United States NLM ID: 101572652 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2164-554X (Electronic) Linking ISSN: 21645515 NLM ISO Abbreviation: Hum Vaccin Immunother Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39993937
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Martinon-Torres+F%22">Martinon-Torres F</searchLink>; Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de Investigación Sanitaria de Santiago (IDIS), Santiago de Compostela, Galicia, Spain.; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain.; Translational Pediatrics and Infectious Diseases, Hospital Clínico Universitario and University of Santiago de Compostela (USC), Santiago de Compostela, Spain.<br /><searchLink fieldCode="AU" term="%22Lamberth+E%22">Lamberth E</searchLink>; Pfizer Vaccine Research and Development, Pfizer Inc, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Natalini+Martinez+S%22">Natalini Martinez S</searchLink>; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Salamanca+de+la+Cueva+I%22">Salamanca de la Cueva I</searchLink>; Unidad de Investigación, Grupo IHP (Instituto Hispalense de Pediatría), Sevilla, Spain.<br /><searchLink fieldCode="AU" term="%22Zolotas+L%22">Zolotas L</searchLink>; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK.<br /><searchLink fieldCode="AU" term="%22Oladipupo+I%22">Oladipupo I</searchLink>; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Maguire+JD%22">Maguire JD</searchLink>; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22Trammel+J%22">Trammel J</searchLink>; Vaccine Research Department, Instituto de Investigación Sanitaria HM, Madrid, Spain.<br /><searchLink fieldCode="AU" term="%22O'Neill+R%22">O'Neill R</searchLink>; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Liberator+PA%22">Liberator PA</searchLink>; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Peyrani+P%22">Peyrani P</searchLink>; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Jodar+L%22">Jodar L</searchLink>; Pfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Inc, Collegeville, PA, USA.<br /><searchLink fieldCode="AU" term="%22Gruber+WC%22">Gruber WC</searchLink>; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+AS%22">Anderson AS</searchLink>; Pfizer Vaccine Clinical Research and Development, Pfizer Inc, Pearl River, NY, USA.<br /><searchLink fieldCode="AU" term="%22Beeslaar+J%22">Beeslaar J</searchLink>; Pfizer Vaccine Research and Development, Pfizer Ltd, Marlow, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101572652%22">Human vaccines & immunotherapeutics</searchLink> [Hum Vaccin Immunother] 2025 Dec; Vol. 21 (1), pp. 2463194. <i>Date of Electronic Publication: </i>2025 Feb 24.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101572652 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2164-554X (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2221645515%22">21645515 </searchLink><i>NLM ISO Abbreviation: </i>Hum Vaccin Immunother <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39993937
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1080/21645515.2025.2463194
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 2463194
    Titles:
      – TitleFull: Safety, tolerability, and immunogenicity of pentavalent meningococcal MenABCWY vaccine in healthy infants: A phase 2b randomized clinical trial.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Martinon-Torres F
      – PersonEntity:
          Name:
            NameFull: Lamberth E
      – PersonEntity:
          Name:
            NameFull: Natalini Martinez S
      – PersonEntity:
          Name:
            NameFull: Salamanca de la Cueva I
      – PersonEntity:
          Name:
            NameFull: Zolotas L
      – PersonEntity:
          Name:
            NameFull: Oladipupo I
      – PersonEntity:
          Name:
            NameFull: Maguire JD
      – PersonEntity:
          Name:
            NameFull: Trammel J
      – PersonEntity:
          Name:
            NameFull: O'Neill R
      – PersonEntity:
          Name:
            NameFull: Liberator PA
      – PersonEntity:
          Name:
            NameFull: Peyrani P
      – PersonEntity:
          Name:
            NameFull: Jodar L
      – PersonEntity:
          Name:
            NameFull: Gruber WC
      – PersonEntity:
          Name:
            NameFull: Anderson AS
      – PersonEntity:
          Name:
            NameFull: Beeslaar J
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 12
              Text: 2025 Dec
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2164-554X
          Numbering:
            – Type: volume
              Value: 21
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Human vaccines & immunotherapeutics
              Type: main
ResultId 1